Certain somatic SNVs were metastasis-specific; including mutations inATRX,CDKN1B,MXRA5 (leading to the activation of a cryptic splice site and loss of mRNA),SMARCA2, and the loss ofUBE4B. Additional mutations inATRX, and splice site loss ofPYGL, leading to intron retention observed in primary and metastatic tumors. This evidence concerns the gene SMARCA2 and metastatic neoplasm.